Viridian Therapeutics, Inc. - Common Stock (VRDN)

The company's drug led to an improvement in diplopia, or double vision, an area where Amgen's Tepezza hasn't worked.

The results are also promising for the next-generation version of that drug.

Viridian Therapeutics announced promising topline data from the THRIVE phase 3 trial of VRDN-001 (veligrotug) for active thyroid eye disease meeting all primary and secondary endpoints. Viridian plans to submit an FDA application for veligrotug in 2025.

VRDN stock results show that Viridian Therapeutics missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.

Biogen has $8 billion to $10 billion in dry powder for acquisitions. Here are three names the company could examine.

Discover three top high-growth small-cap stocks, fueled by potential rate cuts and promising prospects in the second half of 2024.